Key result
Validated growth prediction models forecast individual GH responses in children with GHD or ISS.
Why the study?
There is a principal difference between using regression results from groups and using validated prediction models for individual children to predict growth response to GH treatment.
Growth prediction models enable individualized growth hormone dosing for children with growth disorders.
May inform individualized GH dosing in GHD/ISS; leaves open prospective validation before practice change.
There is a principal and qualitative difference between using regression results on data from groups of children, and using validated prediction models for individual children. Using accurate models, it is now possible to predict the growth response to growth hormone (GH) treatment in a slowly growing child with GH deficiency (GHD) or in a child with idiopathic short stature (ISS). The growth response to the standard dose of GH can be regarded as a bioassay for GH (i.e. the tissue GH responsiveness) and the information on this growth response can be used for different purposes: to decide about treatment or not, for monitoring, and for adjusting the GH dose in order to reach a defined goal for height. This last concept is now used in an ongoing prospective randomized GH dose-finding trial.
No takes yet. Share an insight, caveat, or question.
Kriström et al. (2002) conducted a review in Growth hormone deficiency (GHD) or idiopathic short stature (ISS). Growth prediction models was evaluated. Validated growth prediction models can predict individual growth responses to growth hormone treatment in children with GHD or ISS, aiding in treatment decisions, monitoring, and dose adjustment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: